Steve Lamola

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial

S. Lamola, M. Lal, P. Pitisuttithum, 2022, eClinicalMedicine.

Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial

S. Lamola, M. Lal, P. Pitisuttithum, 2021, medRxiv.

Relationship between age, molecular markers, and response to sulphadoxine–pyrimethamine treatment in Kampala, Uganda

S. Lamola, P. Rosenthal, G. Dorsey, 2004, Tropical medicine & international health : TM & IH.

Meningococcal ACWYX conjugate vaccine in 2–29 year-olds in Mali and Gambia

S. Lamola, Evangelos Simeonidis, Pankaj Sharma, 2023, The New England journal of medicine.

The Effect of Ethnicity in the Rate of Beta Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis.

Kathleen C. Fraser, Mark S. Anderson, Renee A. Davis, 2020, The Journal of clinical endocrinology and metabolism.

Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial.

S. Lamola, D. Weiner, D. Goldblatt, 2019, Vaccine.

Effects of creating visual illness narratives on quality of life with asthma: a pilot intervention study.

M. Rich, S. Lamola, E. Woods, 2006, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Asthma in Life Context: Video Intervention/Prevention Assessment (VIA)

M. Rich, S. Lamola, C. Amory, 2000, Pediatrics.

Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.

Douglas J. Taylor, S. Lamola, D. Goldblatt, 2021, The Lancet. Infectious diseases.